Aspire Biopharma Holdings (ASBP) Accumulated Expenses (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Accumulated Expenses came in at $714088.0 in Q2 2026, up 88.82% year-over-year from $378181.0 in Q2 2025, and up 61.7% quarter-over-quarter from $441614.0 in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Accumulated Expenses (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Accumulated Expenses for 2 consecutive years, with $714088.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Accumulated Expenses rose 88.82% year-over-year to $714088.0 in Q2 2026; TTM through Jun 2026 was $714088.0, a 88.82% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, changed N/A from the prior year.
- Accumulated Expenses was $714088.0 for Q2 2026 at Aspire Biopharma Holdings, up from $441614.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.0 million in Q4 2025 and troughed at $266930.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 714,088.00 |
| Mar 31, 2026 | 441,614.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 266,930.00 |
| Jun 30, 2025 | 378,181.00 |
| Mar 31, 2025 | 319,067.00 |